PTPRD and CNTNAP2 as markers of tumor aggressiveness in oligodendrogliomas.
washington; isb; seattle; genomics
Oligodendrogliomas are typically associated with the most favorable prognosis among diffuse gliomas. However, many of the tumors progress, eventually leading to patient death. To characterize the changes associated with oligodendroglioma recurrence and progression, we analyzed two recurrent oligodendroglioma tumors upon diagnosis and after tumor relapse based on whole-genome and RNA sequencing. Relapsed tumors were diagnosed as glioblastomas with an oligodendroglioma component before the World Health Organization classification update in 2016. Both patients died within 12 months after relapse. One patient carried an inactivating POLE mutation leading to a clearly hypermutated progressed tumor. Strikingly, both relapsed tumors carried focal chromosomal rearrangements in PTPRD and CNTNAP2 genes with associated decreased gene expression. TP53 mutation was also detected in both patients after tumor relapse. In The Cancer Genome Atlas (TCGA) diffuse glioma cohort, PTPRD and CNTNAP2 expression decreased by tumor grade in oligodendrogliomas and PTPRD expression also in IDH-mutant astrocytomas. Low expression of the genes was associated with poor overall survival. Our analysis provides information about aggressive oligodendrogliomas with worse prognosis and suggests that PTPRD and CNTNAP2 expression could represent an informative marker for their stratification.
Institute for Systems Biology
Rautajoki, Kirsi J; Jaatinen, Serafiina; Tiihonen, Aliisa M; Annala, Matti; Vuorinen, Elisa M; Kivinen, Anni; Rauhala, Minna J; Maass, Kendra K; Pajtler, Kristian W; Yli-Harja, Olli; Helén, Pauli; Haapasalo, Joonas; Haapasalo, Hannu; Zhang, Wei; and Nykter, Matti, "PTPRD and CNTNAP2 as markers of tumor aggressiveness in oligodendrogliomas." (2022). Articles, Abstracts, and Reports. 6442.